Advanced search×

Diabetic neuropathy: Mechanisms to management

Pharmacol Ther 120(1):34 (2008) PMID 18616962

Neuropathy is the most common and debilitating complication of diabetes and results in pain, decreased motility, and amputation. Diabetic neuropathy encompasses a variety of forms whose impact ranges from discomfort to death. Hyperglycemia induces oxidative stress in diabetic neurons and results in activation of multiple biochemical pathways. These activated pathways are a major source of damage and are potential therapeutic targets in diabetic neuropathy. Though therapies are available to alleviate the symptoms of diabetic neuropathy, few options are available to eliminate the root causes. The immense physical, psychological, and economic cost of diabetic neuropathy underscore the need for causally targeted therapies. This review covers the pathology, epidemiology, biochemical pathways, and prevention of diabetic neuropathy, as well as discusses current symptomatic and causal therapies and novel approaches to identify therapeutic targets.

DOI: 10.1016/j.pharmthera.2008.05.005
Version: za2963e q8zae q8zb7 q8zc5 q8zd6 q8ze5 q8zfa q8zg9

Similar articles you may find interesting…

  1. Factors associated with reduced efficacy of sitagliptin therapy: analysis of 93 patients with type 2 diabetes treated for 1.5 years or longe...

    J Clin Med Res 5(3):217-21 (2013) PMID 23671547

    Several studies have shown the effectiveness of sitagliptin, a dipeptidyl peptidase-4 inhibitor, for type 2 diabetes, with a hypoglycemic effect being demonstrated both when it is administered alone or in combination with other oral antidiabetic agents. However, there are few reports...
  2. Deep wound cultures and bone biopsy in diabetic foot osteomyelitis.

    Diabetes Metab Res Rev (2013) PMID 23653368

    Deep wound cultures correlate well with osseous cultures and provide a sensitive method in assessing and targeting likely pathogens that cause osseous infections. This will help aid the clinician in guiding antibiotic therapy in centers where bone biopsies may not be readily available. This article...
  3. Transforming Growth Factor-β induced cross talk between p53 and a microRNA in the pathogenesis of Diabetic Nephropathy.

    Diabetes (2013) PMID 23649518

    We report that expression levels of transforming growth factor-β1 (TGF-β), p53 and microRNA-192 (miR-192), are increased in the renal cortex of diabetic mice, and this is associated with enhanced glomerular expansion and fibrosis relative to non-diabetic mice. Targeting miR-192 with locked-nucleic...